Replies to post #251459 on Biotech Values

[oc631]

continued clinical advancement of the ex-vivo oncology construct CT-0525+Pembro in HER2+ solid tumors.

One clarification and a correction. The data for CAR-Monocyte CT-525 that will be released in Q4 will be monotherapy. After reviewing the CT-508/Pembro data the company fully believes a combination with a checkpoint inhibitor would be synergistic and they are moving in that direction. The program in liver fibrosis will be a engineered macrophage and not a CAR which makes the halting of CT-1119 even more of a mystery (to me).